Trial Outcomes & Findings for Cancer in Patients With Gabapentin (GPRD) (NCT NCT01236053)
NCT ID: NCT01236053
Last Updated: 2017-07-06
Results Overview
Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).
COMPLETED
2323608 participants
The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
2017-07-06
Participant Flow
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a patient cohort. All diagnoses and treatments are recorded in the course of routine medical practice.
Actual number of patients may be less, as it is possible for a patient to be represented in more than 1 of the 22 arms (See "Participant Flow: Overall Study" Table) because of the risk set sampling.
Participant milestones
| Measure |
All-Cancer: Cases
Incidence of all cancers defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
All-Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Stomach Cancer: Cases
Incidence of stomach cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Stomach Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Anal Cancer: Cases
Incidence of anal cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Anal Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Lung Cancer: Cases
Incidence of lung cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Lung Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Bone/Joint Cancer: Cases
Incidence of bone/joint cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Bone/Joint Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Breast Cancer: Cases
Incidence of breast cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Breast Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Penile Cancer: Cases
Incidence of penile cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Penile Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Bladder Cancer: Cases
Incidence of bladder cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Bladder Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Other Nervous System Cancer: Cases
Incidence of other nervous system cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Other Nervous System Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Pancreatic Cancer: Cases
Incidence of pancreatic cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Pancreatic Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Renal Cancer: Cases
Incidence of renal cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Renal Cancer: Controls
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
179138
|
1710950
|
1877
|
17853
|
212
|
2067
|
10855
|
102836
|
300
|
2935
|
19564
|
188924
|
148
|
1396
|
4600
|
43559
|
38
|
380
|
2155
|
20382
|
1272
|
12167
|
|
Overall Study
COMPLETED
|
179138
|
1710950
|
1877
|
17853
|
212
|
2067
|
10855
|
102836
|
300
|
2935
|
19564
|
188924
|
148
|
1396
|
4600
|
43559
|
38
|
380
|
2155
|
20382
|
1272
|
12167
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Cancer in Patients With Gabapentin (GPRD)
Baseline characteristics by cohort
| Measure |
All-Cancer: Cases
n=179138 Participants
Incidence of all cancers defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
All-Cancer: Controls
n=1710950 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Stomach Cancer: Cases
n=1877 Participants
Incidence of stomach cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Stomach Cancer: Controls
n=17853 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Anal Cancer: Cases
n=212 Participants
Incidence of anal cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Anal Cancer: Controls
n=2067 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Lung Cancer: Cases
n=10855 Participants
Incidence of lung cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Lung Cancer: Controls
n=102836 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Bone/Joint Cancer: Cases
n=300 Participants
Incidence of bone/joint cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Bone/Joint Cancer: Controls
n=2935 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Breast Cancer: Cases
n=19564 Participants
Incidence of breast cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Breast Cancer: Controls
n=188924 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Penile Cancer: Cases
n=148 Participants
Incidence of penile cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Penile Cancer: Controls
n=1396 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Bladder Cancer: Cases
n=4600 Participants
Incidence of bladder cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Bladder Cancer: Controls
n=43559 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Other Nervous System Cancer: Cases
n=38 Participants
Incidence of other nervous system cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Other Nervous System Cancer: Controls
n=380 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Pancreatic Cancer: Cases
n=2155 Participants
Incidence of pancreatic cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Pancreatic Cancer: Controls
n=20382 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Renal Cancer: Cases
n=1272 Participants
Incidence of renal cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded.
|
Renal Cancer: Controls
n=12167 Participants
Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls.
|
Total
n=2323608 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Customized
< 40 years
|
10246 participants
n=5 Participants
|
101968 participants
n=7 Participants
|
16 participants
n=5 Participants
|
155 participants
n=4 Participants
|
12 participants
n=21 Participants
|
118 participants
n=10 Participants
|
36 participants
n=115 Participants
|
369 participants
n=6 Participants
|
120 participants
n=6 Participants
|
1173 participants
n=64 Participants
|
915 participants
n=17 Participants
|
9346 participants
n=21 Participants
|
9 participants
n=22 Participants
|
90 participants
n=8 Participants
|
56 participants
n=16 Participants
|
552 participants
n=135 Participants
|
5 participants
n=136 Participants
|
54 participants
n=44 Participants
|
11 participants
n=667 Participants
|
132 participants
n=7 Participants
|
31 participants
n=6 Participants
|
317 participants
n=10 Participants
|
125731 participants
n=14 Participants
|
|
Age, Customized
40-49 years
|
13112 participants
n=5 Participants
|
132244 participants
n=7 Participants
|
48 participants
n=5 Participants
|
469 participants
n=4 Participants
|
18 participants
n=21 Participants
|
200 participants
n=10 Participants
|
294 participants
n=115 Participants
|
2973 participants
n=6 Participants
|
21 participants
n=6 Participants
|
254 participants
n=64 Participants
|
2827 participants
n=17 Participants
|
29167 participants
n=21 Participants
|
16 participants
n=22 Participants
|
154 participants
n=8 Participants
|
120 participants
n=16 Participants
|
1285 participants
n=135 Participants
|
8 participants
n=136 Participants
|
78 participants
n=44 Participants
|
65 participants
n=667 Participants
|
669 participants
n=7 Participants
|
99 participants
n=6 Participants
|
990 participants
n=10 Participants
|
185111 participants
n=14 Participants
|
|
Age, Customized
50-59 years
|
28392 participants
n=5 Participants
|
279797 participants
n=7 Participants
|
135 participants
n=5 Participants
|
1388 participants
n=4 Participants
|
47 participants
n=21 Participants
|
467 participants
n=10 Participants
|
1256 participants
n=115 Participants
|
12388 participants
n=6 Participants
|
46 participants
n=6 Participants
|
422 participants
n=64 Participants
|
5319 participants
n=17 Participants
|
51266 participants
n=21 Participants
|
30 participants
n=22 Participants
|
300 participants
n=8 Participants
|
547 participants
n=16 Participants
|
5296 participants
n=135 Participants
|
5 participants
n=136 Participants
|
54 participants
n=44 Participants
|
261 participants
n=667 Participants
|
2564 participants
n=7 Participants
|
249 participants
n=6 Participants
|
2406 participants
n=10 Participants
|
392635 participants
n=14 Participants
|
|
Age, Customized
60-69 years
|
43077 participants
n=5 Participants
|
415567 participants
n=7 Participants
|
395 participants
n=5 Participants
|
3850 participants
n=4 Participants
|
45 participants
n=21 Participants
|
464 participants
n=10 Participants
|
2944 participants
n=115 Participants
|
28526 participants
n=6 Participants
|
38 participants
n=6 Participants
|
360 participants
n=64 Participants
|
4665 participants
n=17 Participants
|
44769 participants
n=21 Participants
|
32 participants
n=22 Participants
|
320 participants
n=8 Participants
|
1127 participants
n=16 Participants
|
11021 participants
n=135 Participants
|
9 participants
n=136 Participants
|
78 participants
n=44 Participants
|
515 participants
n=667 Participants
|
5043 participants
n=7 Participants
|
362 participants
n=6 Participants
|
3498 participants
n=10 Participants
|
566705 participants
n=14 Participants
|
|
Age, Customized
70-79 years
|
50072 participants
n=5 Participants
|
475887 participants
n=7 Participants
|
679 participants
n=5 Participants
|
6559 participants
n=4 Participants
|
50 participants
n=21 Participants
|
440 participants
n=10 Participants
|
4092 participants
n=115 Participants
|
38557 participants
n=6 Participants
|
51 participants
n=6 Participants
|
501 participants
n=64 Participants
|
3334 participants
n=17 Participants
|
32051 participants
n=21 Participants
|
44 participants
n=22 Participants
|
388 participants
n=8 Participants
|
1644 participants
n=16 Participants
|
15471 participants
n=135 Participants
|
4 participants
n=136 Participants
|
48 participants
n=44 Participants
|
716 participants
n=667 Participants
|
6813 participants
n=7 Participants
|
361 participants
n=6 Participants
|
3399 participants
n=10 Participants
|
641161 participants
n=14 Participants
|
|
Age, Customized
80+ years
|
34239 participants
n=5 Participants
|
305487 participants
n=7 Participants
|
604 participants
n=5 Participants
|
5432 participants
n=4 Participants
|
40 participants
n=21 Participants
|
378 participants
n=10 Participants
|
2233 participants
n=115 Participants
|
20023 participants
n=6 Participants
|
24 participants
n=6 Participants
|
225 participants
n=64 Participants
|
2504 participants
n=17 Participants
|
22325 participants
n=21 Participants
|
17 participants
n=22 Participants
|
144 participants
n=8 Participants
|
1106 participants
n=16 Participants
|
9934 participants
n=135 Participants
|
7 participants
n=136 Participants
|
68 participants
n=44 Participants
|
587 participants
n=667 Participants
|
5161 participants
n=7 Participants
|
170 participants
n=6 Participants
|
1557 participants
n=10 Participants
|
412265 participants
n=14 Participants
|
|
Sex: Female, Male
Female
|
92099 Participants
n=5 Participants
|
883331 Participants
n=7 Participants
|
716 Participants
n=5 Participants
|
6789 Participants
n=4 Participants
|
133 Participants
n=21 Participants
|
1294 Participants
n=10 Participants
|
4259 Participants
n=115 Participants
|
40345 Participants
n=6 Participants
|
156 Participants
n=6 Participants
|
1538 Participants
n=64 Participants
|
19564 Participants
n=17 Participants
|
188924 Participants
n=21 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=8 Participants
|
1229 Participants
n=16 Participants
|
11552 Participants
n=135 Participants
|
14 Participants
n=136 Participants
|
140 Participants
n=44 Participants
|
1109 Participants
n=667 Participants
|
10530 Participants
n=7 Participants
|
507 Participants
n=6 Participants
|
4820 Participants
n=10 Participants
|
1269049 Participants
n=14 Participants
|
|
Sex: Female, Male
Male
|
87039 Participants
n=5 Participants
|
827619 Participants
n=7 Participants
|
1161 Participants
n=5 Participants
|
11064 Participants
n=4 Participants
|
79 Participants
n=21 Participants
|
773 Participants
n=10 Participants
|
6596 Participants
n=115 Participants
|
62491 Participants
n=6 Participants
|
144 Participants
n=6 Participants
|
1397 Participants
n=64 Participants
|
0 Participants
n=17 Participants
|
0 Participants
n=21 Participants
|
148 Participants
n=22 Participants
|
1396 Participants
n=8 Participants
|
3371 Participants
n=16 Participants
|
32007 Participants
n=135 Participants
|
24 Participants
n=136 Participants
|
240 Participants
n=44 Participants
|
1046 Participants
n=667 Participants
|
9852 Participants
n=7 Participants
|
765 Participants
n=6 Participants
|
7347 Participants
n=10 Participants
|
1054559 Participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from registration to index date
0-1 years
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
11846 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
11846 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from registration to index date
2-3 years
|
12001 participants
n=5 Participants
|
99830 participants
n=7 Participants
|
115 participants
n=5 Participants
|
866 participants
n=4 Participants
|
14 participants
n=21 Participants
|
135 participants
n=10 Participants
|
644 participants
n=115 Participants
|
5014 participants
n=6 Participants
|
35 participants
n=6 Participants
|
331 participants
n=64 Participants
|
1361 participants
n=17 Participants
|
11846 participants
n=21 Participants
|
9 participants
n=22 Participants
|
73 participants
n=8 Participants
|
251 participants
n=16 Participants
|
2007 participants
n=135 Participants
|
2 participants
n=136 Participants
|
13 participants
n=44 Participants
|
118 participants
n=667 Participants
|
968 participants
n=7 Participants
|
91 participants
n=6 Participants
|
762 participants
n=10 Participants
|
136486 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from registration to index date
4-5 years
|
12675 participants
n=5 Participants
|
108112 participants
n=7 Participants
|
123 participants
n=5 Participants
|
1048 participants
n=4 Participants
|
20 participants
n=21 Participants
|
164 participants
n=10 Participants
|
708 participants
n=115 Participants
|
5868 participants
n=6 Participants
|
35 participants
n=6 Participants
|
308 participants
n=64 Participants
|
1426 participants
n=17 Participants
|
12724 participants
n=21 Participants
|
15 participants
n=22 Participants
|
136 participants
n=8 Participants
|
283 participants
n=16 Participants
|
2403 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
122 participants
n=667 Participants
|
1028 participants
n=7 Participants
|
72 participants
n=6 Participants
|
695 participants
n=10 Participants
|
147965 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from registration to index date
6-7 years
|
13403 participants
n=5 Participants
|
119691 participants
n=7 Participants
|
157 participants
n=5 Participants
|
1321 participants
n=4 Participants
|
13 participants
n=21 Participants
|
121 participants
n=10 Participants
|
802 participants
n=115 Participants
|
6978 participants
n=6 Participants
|
29 participants
n=6 Participants
|
264 participants
n=64 Participants
|
1508 participants
n=17 Participants
|
14037 participants
n=21 Participants
|
12 participants
n=22 Participants
|
104 participants
n=8 Participants
|
304 participants
n=16 Participants
|
2694 participants
n=135 Participants
|
5 participants
n=136 Participants
|
41 participants
n=44 Participants
|
173 participants
n=667 Participants
|
1418 participants
n=7 Participants
|
95 participants
n=6 Participants
|
839 participants
n=10 Participants
|
164009 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from registration to index date
8+ years
|
141059 participants
n=5 Participants
|
1383317 participants
n=7 Participants
|
1482 participants
n=5 Participants
|
14618 participants
n=4 Participants
|
165 participants
n=21 Participants
|
1647 participants
n=10 Participants
|
8681 participants
n=115 Participants
|
84976 participants
n=6 Participants
|
201 participants
n=6 Participants
|
2032 participants
n=64 Participants
|
15269 participants
n=17 Participants
|
150317 participants
n=21 Participants
|
112 participants
n=22 Participants
|
1083 participants
n=8 Participants
|
3762 participants
n=16 Participants
|
36455 participants
n=135 Participants
|
31 participants
n=136 Participants
|
326 participants
n=44 Participants
|
1742 participants
n=667 Participants
|
16968 participants
n=7 Participants
|
1014 participants
n=6 Participants
|
9871 participants
n=10 Participants
|
1875128 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from cohort entry to index date
0-1 years
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
3216 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
3216 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from cohort entry to index date
2-3 years
|
24693 participants
n=5 Participants
|
226195 participants
n=7 Participants
|
351 participants
n=5 Participants
|
3216 participants
n=4 Participants
|
32 participants
n=21 Participants
|
319 participants
n=10 Participants
|
1627 participants
n=115 Participants
|
14736 participants
n=6 Participants
|
48 participants
n=6 Participants
|
458 participants
n=64 Participants
|
2784 participants
n=17 Participants
|
26004 participants
n=21 Participants
|
24 participants
n=22 Participants
|
212 participants
n=8 Participants
|
592 participants
n=16 Participants
|
5351 participants
n=135 Participants
|
2 participants
n=136 Participants
|
20 participants
n=44 Participants
|
310 participants
n=667 Participants
|
2835 participants
n=7 Participants
|
186 participants
n=6 Participants
|
1704 participants
n=10 Participants
|
311699 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from cohort entry to index date
4-5 years
|
24123 participants
n=5 Participants
|
223084 participants
n=7 Participants
|
281 participants
n=5 Participants
|
2628 participants
n=4 Participants
|
32 participants
n=21 Participants
|
288 participants
n=10 Participants
|
1489 participants
n=115 Participants
|
13563 participants
n=6 Participants
|
48 participants
n=6 Participants
|
451 participants
n=64 Participants
|
2718 participants
n=17 Participants
|
25616 participants
n=21 Participants
|
28 participants
n=22 Participants
|
264 participants
n=8 Participants
|
609 participants
n=16 Participants
|
5502 participants
n=135 Participants
|
2 participants
n=136 Participants
|
20 participants
n=44 Participants
|
283 participants
n=667 Participants
|
2596 participants
n=7 Participants
|
149 participants
n=6 Participants
|
1388 participants
n=10 Participants
|
305162 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from cohort entry to index date
6-7 years
|
25608 participants
n=5 Participants
|
241586 participants
n=7 Participants
|
231 participants
n=5 Participants
|
2108 participants
n=4 Participants
|
26 participants
n=21 Participants
|
257 participants
n=10 Participants
|
1577 participants
n=115 Participants
|
14855 participants
n=6 Participants
|
49 participants
n=6 Participants
|
490 participants
n=64 Participants
|
2830 participants
n=17 Participants
|
27109 participants
n=21 Participants
|
17 participants
n=22 Participants
|
159 participants
n=8 Participants
|
618 participants
n=16 Participants
|
5824 participants
n=135 Participants
|
6 participants
n=136 Participants
|
60 participants
n=44 Participants
|
318 participants
n=667 Participants
|
2972 participants
n=7 Participants
|
165 participants
n=6 Participants
|
1564 participants
n=10 Participants
|
328429 participants
n=14 Participants
|
|
Number of participants with the indicated duration of follow-up from cohort entry to index date
8+ years
|
104714 participants
n=5 Participants
|
1020085 participants
n=7 Participants
|
1014 participants
n=5 Participants
|
9901 participants
n=4 Participants
|
122 participants
n=21 Participants
|
1203 participants
n=10 Participants
|
6162 participants
n=115 Participants
|
59682 participants
n=6 Participants
|
155 participants
n=6 Participants
|
1536 participants
n=64 Participants
|
11232 participants
n=17 Participants
|
110195 participants
n=21 Participants
|
79 participants
n=22 Participants
|
761 participants
n=8 Participants
|
2781 participants
n=16 Participants
|
26882 participants
n=135 Participants
|
28 participants
n=136 Participants
|
280 participants
n=44 Participants
|
1244 participants
n=667 Participants
|
11979 participants
n=7 Participants
|
772 participants
n=6 Participants
|
7511 participants
n=10 Participants
|
1378318 participants
n=14 Participants
|
|
Number of participants with the indicated Body Mass Index (BMI)
BMI: < 18.5 kg/m^2
|
2393 participants
n=5 Participants
|
19861 participants
n=7 Participants
|
30 participants
n=5 Participants
|
190 participants
n=4 Participants
|
5 participants
n=21 Participants
|
30 participants
n=10 Participants
|
255 participants
n=115 Participants
|
1081 participants
n=6 Participants
|
7 participants
n=6 Participants
|
38 participants
n=64 Participants
|
267 participants
n=17 Participants
|
3059 participants
n=21 Participants
|
1 participants
n=22 Participants
|
7 participants
n=8 Participants
|
52 participants
n=16 Participants
|
380 participants
n=135 Participants
|
0 participants
n=136 Participants
|
4 participants
n=44 Participants
|
30 participants
n=667 Participants
|
232 participants
n=7 Participants
|
7 participants
n=6 Participants
|
128 participants
n=10 Participants
|
28057 participants
n=14 Participants
|
|
Number of participants with the indicated Body Mass Index (BMI)
BMI: 18.5 to 24.99 kg/m^2
|
61913 participants
n=5 Participants
|
569726 participants
n=7 Participants
|
580 participants
n=5 Participants
|
5429 participants
n=4 Participants
|
82 participants
n=21 Participants
|
674 participants
n=10 Participants
|
3912 participants
n=115 Participants
|
31787 participants
n=6 Participants
|
72 participants
n=6 Participants
|
741 participants
n=64 Participants
|
7813 participants
n=17 Participants
|
75516 participants
n=21 Participants
|
42 participants
n=22 Participants
|
420 participants
n=8 Participants
|
1408 participants
n=16 Participants
|
13224 participants
n=135 Participants
|
11 participants
n=136 Participants
|
106 participants
n=44 Participants
|
662 participants
n=667 Participants
|
6313 participants
n=7 Participants
|
331 participants
n=6 Participants
|
3753 participants
n=10 Participants
|
784515 participants
n=14 Participants
|
|
Number of participants with the indicated Body Mass Index (BMI)
BMI: 25 to 29.99 kg/m^2
|
54471 participants
n=5 Participants
|
508109 participants
n=7 Participants
|
579 participants
n=5 Participants
|
5483 participants
n=4 Participants
|
55 participants
n=21 Participants
|
581 participants
n=10 Participants
|
3070 participants
n=115 Participants
|
33035 participants
n=6 Participants
|
70 participants
n=6 Participants
|
580 participants
n=64 Participants
|
5054 participants
n=17 Participants
|
47989 participants
n=21 Participants
|
50 participants
n=22 Participants
|
461 participants
n=8 Participants
|
1591 participants
n=16 Participants
|
14390 participants
n=135 Participants
|
11 participants
n=136 Participants
|
111 participants
n=44 Participants
|
662 participants
n=667 Participants
|
6313 participants
n=7 Participants
|
447 participants
n=6 Participants
|
3958 participants
n=10 Participants
|
687070 participants
n=14 Participants
|
|
Number of participants with the indicated Body Mass Index (BMI)
BMI: 30 kg/m^2 or greater
|
22152 participants
n=5 Participants
|
206232 participants
n=7 Participants
|
245 participants
n=5 Participants
|
2001 participants
n=4 Participants
|
21 participants
n=21 Participants
|
254 participants
n=10 Participants
|
1097 participants
n=115 Participants
|
12814 participants
n=6 Participants
|
25 participants
n=6 Participants
|
285 participants
n=64 Participants
|
2773 participants
n=17 Participants
|
25819 participants
n=21 Participants
|
22 participants
n=22 Participants
|
142 participants
n=8 Participants
|
587 participants
n=16 Participants
|
5117 participants
n=135 Participants
|
7 participants
n=136 Participants
|
37 participants
n=44 Participants
|
294 participants
n=667 Participants
|
2492 participants
n=7 Participants
|
245 participants
n=6 Participants
|
1626 participants
n=10 Participants
|
284287 participants
n=14 Participants
|
|
Number of participants with the indicated Body Mass Index (BMI)
BMI: Missing
|
38209 participants
n=5 Participants
|
407022 participants
n=7 Participants
|
443 participants
n=5 Participants
|
4750 participants
n=4 Participants
|
49 participants
n=21 Participants
|
528 participants
n=10 Participants
|
2521 participants
n=115 Participants
|
24119 participants
n=6 Participants
|
126 participants
n=6 Participants
|
1291 participants
n=64 Participants
|
3657 participants
n=17 Participants
|
36541 participants
n=21 Participants
|
33 participants
n=22 Participants
|
366 participants
n=8 Participants
|
962 participants
n=16 Participants
|
10448 participants
n=135 Participants
|
9 participants
n=136 Participants
|
122 participants
n=44 Participants
|
507 participants
n=667 Participants
|
5027 participants
n=7 Participants
|
242 participants
n=6 Participants
|
2702 participants
n=10 Participants
|
539674 participants
n=14 Participants
|
|
Number of participants with the indicated smoking status
Current Smoker
|
38033 participants
n=5 Participants
|
306184 participants
n=7 Participants
|
375 participants
n=5 Participants
|
2902 participants
n=4 Participants
|
63 participants
n=21 Participants
|
379 participants
n=10 Participants
|
4806 participants
n=115 Participants
|
18856 participants
n=6 Participants
|
51 participants
n=6 Participants
|
476 participants
n=64 Participants
|
3572 participants
n=17 Participants
|
34818 participants
n=21 Participants
|
51 participants
n=22 Participants
|
297 participants
n=8 Participants
|
1310 participants
n=16 Participants
|
7502 participants
n=135 Participants
|
10 participants
n=136 Participants
|
71 participants
n=44 Participants
|
518 participants
n=667 Participants
|
3368 participants
n=7 Participants
|
309 participants
n=6 Participants
|
2324 participants
n=10 Participants
|
426275 participants
n=14 Participants
|
|
Number of participants with the indicated smoking status
Ex-Smoker
|
41270 participants
n=5 Participants
|
354651 participants
n=7 Participants
|
531 participants
n=5 Participants
|
4134 participants
n=4 Participants
|
41 participants
n=21 Participants
|
380 participants
n=10 Participants
|
3594 participants
n=115 Participants
|
24290 participants
n=6 Participants
|
43 participants
n=6 Participants
|
385 participants
n=64 Participants
|
3156 participants
n=17 Participants
|
28210 participants
n=21 Participants
|
29 participants
n=22 Participants
|
334 participants
n=8 Participants
|
1307 participants
n=16 Participants
|
11070 participants
n=135 Participants
|
6 participants
n=136 Participants
|
77 participants
n=44 Participants
|
499 participants
n=667 Participants
|
4247 participants
n=7 Participants
|
319 participants
n=6 Participants
|
2768 participants
n=10 Participants
|
481341 participants
n=14 Participants
|
|
Number of participants with the indicated smoking status
Never Smoked
|
85483 participants
n=5 Participants
|
854263 participants
n=7 Participants
|
810 participants
n=5 Participants
|
8540 participants
n=4 Participants
|
83 participants
n=21 Participants
|
1048 participants
n=10 Participants
|
1766 participants
n=115 Participants
|
48127 participants
n=6 Participants
|
133 participants
n=6 Participants
|
1255 participants
n=64 Participants
|
11396 participants
n=17 Participants
|
109463 participants
n=21 Participants
|
58 participants
n=22 Participants
|
587 participants
n=8 Participants
|
1636 participants
n=16 Participants
|
20018 participants
n=135 Participants
|
17 participants
n=136 Participants
|
176 participants
n=44 Participants
|
929 participants
n=667 Participants
|
10455 participants
n=7 Participants
|
570 participants
n=6 Participants
|
5875 participants
n=10 Participants
|
1162688 participants
n=14 Participants
|
|
Number of participants with the indicated smoking status
Unknown
|
14352 participants
n=5 Participants
|
195852 participants
n=7 Participants
|
161 participants
n=5 Participants
|
2277 participants
n=4 Participants
|
25 participants
n=21 Participants
|
260 participants
n=10 Participants
|
689 participants
n=115 Participants
|
11563 participants
n=6 Participants
|
73 participants
n=6 Participants
|
819 participants
n=64 Participants
|
1440 participants
n=17 Participants
|
16433 participants
n=21 Participants
|
10 participants
n=22 Participants
|
178 participants
n=8 Participants
|
347 participants
n=16 Participants
|
4969 participants
n=135 Participants
|
5 participants
n=136 Participants
|
56 participants
n=44 Participants
|
209 participants
n=667 Participants
|
2312 participants
n=7 Participants
|
74 participants
n=6 Participants
|
1200 participants
n=10 Participants
|
253304 participants
n=14 Participants
|
|
Number of participants with the indicated alcohol consumption (per day)
0 units/day
|
36134 participants
n=5 Participants
|
340399 participants
n=7 Participants
|
422 participants
n=5 Participants
|
3817 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
2412 participants
n=115 Participants
|
21471 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
4585 participants
n=17 Participants
|
44823 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
454063 participants
n=14 Participants
|
|
Number of participants with the indicated alcohol consumption (per day)
1-2 units/day
|
86422 participants
n=5 Participants
|
801383 participants
n=7 Participants
|
839 participants
n=5 Participants
|
7659 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
4661 participants
n=115 Participants
|
46769 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
9947 participants
n=17 Participants
|
93964 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
1051644 participants
n=14 Participants
|
|
Number of participants with the indicated alcohol consumption (per day)
3-6 units/day
|
11929 participants
n=5 Participants
|
102201 participants
n=7 Participants
|
115 participants
n=5 Participants
|
1118 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
868 participants
n=115 Participants
|
6843 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
535 participants
n=17 Participants
|
4544 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
128153 participants
n=14 Participants
|
|
Number of participants with the indicated alcohol consumption (per day)
7+ units/day
|
1992 participants
n=5 Participants
|
15014 participants
n=7 Participants
|
18 participants
n=5 Participants
|
157 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
202 participants
n=115 Participants
|
1132 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
50 participants
n=17 Participants
|
399 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
18964 participants
n=14 Participants
|
|
Number of participants with the indicated alcohol consumption (per day)
Missing
|
42661 participants
n=5 Participants
|
451953 participants
n=7 Participants
|
483 participants
n=5 Participants
|
5102 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
2712 participants
n=115 Participants
|
26621 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
4447 participants
n=17 Participants
|
45194 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
579173 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Acid suppressing drugs (>6 mo. before index date)
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
796 participants
n=5 Participants
|
5202 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
5998 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Back pain
|
87337 participants
n=5 Participants
|
765861 participants
n=7 Participants
|
924 participants
n=5 Participants
|
7779 participants
n=4 Participants
|
92 participants
n=21 Participants
|
924 participants
n=10 Participants
|
5626 participants
n=115 Participants
|
46417 participants
n=6 Participants
|
130 participants
n=6 Participants
|
1008 participants
n=64 Participants
|
9603 participants
n=17 Participants
|
91302 participants
n=21 Participants
|
59 participants
n=22 Participants
|
569 participants
n=8 Participants
|
2149 participants
n=16 Participants
|
18811 participants
n=135 Participants
|
23 participants
n=136 Participants
|
192 participants
n=44 Participants
|
1081 participants
n=667 Participants
|
9186 participants
n=7 Participants
|
678 participants
n=6 Participants
|
5473 participants
n=10 Participants
|
1055224 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Benign breast disease
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
894 participants
n=17 Participants
|
5508 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
6402 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Chronic obstructive pulmonary disease (COPD)
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
2532 participants
n=115 Participants
|
6639 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
9171 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Chronic pancreatitis
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
13 participants
n=667 Participants
|
8 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
21 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Current estrogen (within 6 months of index date)
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
2916 participants
n=17 Participants
|
22576 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
25492 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Diabetes
|
15280 participants
n=5 Participants
|
130210 participants
n=7 Participants
|
208 participants
n=5 Participants
|
1592 participants
n=4 Participants
|
17 participants
n=21 Participants
|
139 participants
n=10 Participants
|
1086 participants
n=115 Participants
|
9448 participants
n=6 Participants
|
15 participants
n=6 Participants
|
155 participants
n=64 Participants
|
1162 participants
n=17 Participants
|
9899 participants
n=21 Participants
|
18 participants
n=22 Participants
|
104 participants
n=8 Participants
|
559 participants
n=16 Participants
|
4087 participants
n=135 Participants
|
3 participants
n=136 Participants
|
32 participants
n=44 Participants
|
241 participants
n=667 Participants
|
1415 participants
n=7 Participants
|
155 participants
n=6 Participants
|
968 participants
n=10 Participants
|
176793 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Diuretic use (at any time up to the index date)
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
554 participants
n=6 Participants
|
3815 participants
n=10 Participants
|
4369 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Epilepsy
|
3015 participants
n=5 Participants
|
24226 participants
n=7 Participants
|
32 participants
n=5 Participants
|
271 participants
n=4 Participants
|
8 participants
n=21 Participants
|
23 participants
n=10 Participants
|
214 participants
n=115 Participants
|
1577 participants
n=6 Participants
|
3 participants
n=6 Participants
|
33 participants
n=64 Participants
|
285 participants
n=17 Participants
|
2486 participants
n=21 Participants
|
0 participants
n=22 Participants
|
28 participants
n=8 Participants
|
78 participants
n=16 Participants
|
654 participants
n=135 Participants
|
3 participants
n=136 Participants
|
4 participants
n=44 Participants
|
35 participants
n=667 Participants
|
289 participants
n=7 Participants
|
20 participants
n=6 Participants
|
176 participants
n=10 Participants
|
33460 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Human immunodeficiency virus (HIV)
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
3 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
3 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Human papillomavirus (HPV) (genital)
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
15 participants
n=21 Participants
|
7 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
9 participants
n=22 Participants
|
12 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
43 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Hypertension
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
749 participants
n=6 Participants
|
5580 participants
n=10 Participants
|
6329 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Hysterectomy
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
3563 participants
n=17 Participants
|
34290 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
37853 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Neuropathic pain
|
38561 participants
n=5 Participants
|
338723 participants
n=7 Participants
|
382 participants
n=5 Participants
|
3485 participants
n=4 Participants
|
47 participants
n=21 Participants
|
406 participants
n=10 Participants
|
2485 participants
n=115 Participants
|
21202 participants
n=6 Participants
|
49 participants
n=6 Participants
|
387 participants
n=64 Participants
|
4055 participants
n=17 Participants
|
39494 participants
n=21 Participants
|
25 participants
n=22 Participants
|
229 participants
n=8 Participants
|
998 participants
n=16 Participants
|
8539 participants
n=135 Participants
|
15 participants
n=136 Participants
|
71 participants
n=44 Participants
|
474 participants
n=667 Participants
|
4195 participants
n=7 Participants
|
275 participants
n=6 Participants
|
2434 participants
n=10 Participants
|
466531 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Phimosis
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
54 participants
n=22 Participants
|
31 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
85 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Prior estrogen
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
0 participants
n=5 Participants
|
0 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
6803 participants
n=17 Participants
|
60840 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
67643 participants
n=14 Participants
|
|
Number of participants using indicated class of medications or having the indicated comorbidities
Upper gastro-intestinal disorder
|
0 participants
n=5 Participants
|
0 participants
n=7 Participants
|
442 participants
n=5 Participants
|
2860 participants
n=4 Participants
|
0 participants
n=21 Participants
|
0 participants
n=10 Participants
|
0 participants
n=115 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=64 Participants
|
0 participants
n=17 Participants
|
0 participants
n=21 Participants
|
0 participants
n=22 Participants
|
0 participants
n=8 Participants
|
0 participants
n=16 Participants
|
0 participants
n=135 Participants
|
0 participants
n=136 Participants
|
0 participants
n=44 Participants
|
0 participants
n=667 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=10 Participants
|
3302 participants
n=14 Participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).
Outcome measures
| Measure |
Incident All-cancer Patients
n=179138 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1710950 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
804 participants
|
6507 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
178334 participants
|
1704443 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
1729 participants
|
12470 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
177409 participants
|
1698480 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Outcome measures
| Measure |
Incident All-cancer Patients
n=179138 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1710950 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
216 participants
|
1645 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
269 participants
|
2123 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
177409 participants
|
1698480 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
781 participants
|
5285 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
413 participants
|
3033 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
535 participants
|
4152 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
178334 participants
|
1704443 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
319 participants
|
2739 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Outcome measures
| Measure |
Incident All-cancer Patients
n=179138 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1710950 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
178334 participants
|
1704443 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
258 participants
|
2175 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
269 participants
|
2163 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
277 participants
|
2169 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
177409 participants
|
1698480 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
620 participants
|
4213 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
587 participants
|
4104 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
522 participants
|
4153 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=179138 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1710950 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
76 participants
|
549 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
178334 participants
|
1704443 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
157 participants
|
1217 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
64 participants
|
463 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
25 participants
|
197 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
177409 participants
|
1698480 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
301 participants
|
2499 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
159 participants
|
1207 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Outcome measures
| Measure |
Incident All-cancer Patients
n=179138 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1710950 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
178334 participants
|
1704443 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
269 participants
|
2222 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
268 participants
|
2118 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
267 participants
|
2167 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
177409 participants
|
1698480 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
640 participants
|
4438 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
585 participants
|
3882 participants
|
|
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
504 participants
|
4150 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1877 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=17853 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
5 participants
|
70 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
1872 participants
|
17783 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
13 participants
|
20 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
1864 participants
|
17733 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip\]), T 2 (3-7 prescrip), T 3 (8-298 prescrip). Tertiles without 2 yr lag: T 1 (1-2 prescrip), T 2 (3-7 prescrip), and T 3 (8-388 prescrip). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1877 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=17853 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
7 participants
|
19 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
3 participants
|
46 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
1872 participants
|
17783 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
0 participants
|
29 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
3 participants
|
31 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
1864 participants
|
17733 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
3 participants
|
55 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
2 participants
|
10 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.3-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 m.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1877 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=17853 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
1872 participants
|
17783 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
0 participants
|
24 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
2 participants
|
14 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
3 participants
|
32 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
1864 participants
|
17733 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
4 participants
|
44 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
4 participants
|
30 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
5 participants
|
46 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1877 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=17853 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
2 participants
|
19 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
1872 participants
|
17783 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
2 participants
|
15 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
1 participants
|
8 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
1 participants
|
4 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
1864 participants
|
17733 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
3 participants
|
33 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
1 participants
|
11 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1877 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=17853 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
3 participants
|
21 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
3 participants
|
46 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
1872 participants
|
17783 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
0 participants
|
22 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
2 participants
|
27 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
1864 participants
|
17733 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
6 participants
|
31 participants
|
|
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
4 participants
|
43 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident Anal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=212 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2067 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
4 participants
|
6 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
208 participants
|
2061 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
5 participants
|
15 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
207 participants
|
2052 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=212 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2067 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
208 participants
|
2061 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
2 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
1 participants
|
2 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
1 participants
|
3 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
207 participants
|
2052 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
3 participants
|
7 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
2 participants
|
5 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57 -105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=212 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2067 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
207 participants
|
2052 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
3 participants
|
5 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
208 participants
|
2061 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
2 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
1 participants
|
2 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
1 participants
|
3 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
0 participants
|
5 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
2 participants
|
5 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident anal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=212 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2067 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
208 participants
|
2061 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
207 participants
|
2052 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
2 participants
|
3 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
0 participants
|
1 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 yr lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=212 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2067 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
208 participants
|
2061 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
2 participants
|
1 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
1 participants
|
3 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
1 participants
|
2 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
207 participants
|
2052 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
3 participants
|
7 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
2 participants
|
5 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=10855 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=102836 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
10800 participants
|
102434 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
155 participants
|
783 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
10700 participants
|
102053 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
55 participants
|
402 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Outcome measures
| Measure |
Incident All-cancer Patients
n=10855 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=102836 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
42 participants
|
270 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
13 participants
|
105 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
18 participants
|
137 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
10700 participants
|
102053 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
81 participants
|
327 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
10800 participants
|
102434 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
24 participants
|
160 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
32 participants
|
186 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Outcome measures
| Measure |
Incident All-cancer Patients
n=10855 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=102836 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
10800 participants
|
102434 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
21 participants
|
131 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
15 participants
|
130 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
19 participants
|
141 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
10700 participants
|
102053 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
67 participants
|
267 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
48 participants
|
247 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
40 participants
|
269 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=10855 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=102836 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
11 participants
|
77 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
10800 participants
|
102434 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
10 participants
|
75 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
4 participants
|
24 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
1 participants
|
6 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
10700 participants
|
102053 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
21 participants
|
167 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
4 participants
|
33 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Outcome measures
| Measure |
Incident All-cancer Patients
n=10855 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=102836 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
10800 participants
|
102434 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
21 participants
|
139 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
16 participants
|
120 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
18 participants
|
143 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
10700 participants
|
102053 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
62 participants
|
288 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
56 participants
|
224 participants
|
|
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
37 participants
|
271 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bone/joint cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. Inestimable OR and 95% CI when no gabapentin-exposed cancer cases or no gabapentin-exposed controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=300 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2935 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
0 participants
|
10 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
300 participants
|
2925 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
1 participants
|
19 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
299 participants
|
2916 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=300 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2935 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
300 participants
|
2925 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
0 participants
|
4 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
0 participants
|
2 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
0 participants
|
4 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
299 participants
|
2916 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
1 participants
|
7 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
0 participants
|
4 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
0 participants
|
8 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=300 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2935 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
1 participants
|
5 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
0 participants
|
5 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
0 participants
|
9 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
300 participants
|
2925 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
0 participants
|
4 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
0 participants
|
5 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
299 participants
|
2916 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bone/joint cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=300 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2935 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
300 participants
|
2925 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
299 participants
|
2916 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
0 participants
|
5 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
0 participants
|
0 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=300 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=2935 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
300 participants
|
2925 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
0 participants
|
4 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
0 participants
|
6 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
299 participants
|
2916 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
1 participants
|
8 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
0 participants
|
8 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=19564 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=188924 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
96 participants
|
725 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
19468 participants
|
188199 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
174 participants
|
1392 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
19390 participants
|
187532 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Outcome measures
| Measure |
Incident All-cancer Patients
n=19564 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=188924 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
19468 participants
|
188199 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
38 participants
|
306 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
24 participants
|
182 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
34 participants
|
237 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
19390 participants
|
187532 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
75 participants
|
577 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
32 participants
|
355 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
67 participants
|
460 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Outcome measures
| Measure |
Incident All-cancer Patients
n=19564 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=188924 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
19468 participants
|
188199 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
29 participants
|
245 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
32 participants
|
247 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
35 participants
|
233 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
19390 participants
|
187532 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
58 participants
|
465 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
52 participants
|
473 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
64 participants
|
454 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=19564 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=188924 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
19468 participants
|
188199 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
20 participants
|
131 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
9 participants
|
54 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
2 participants
|
27 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
19390 participants
|
187532 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
46 participants
|
291 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
24 participants
|
133 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
10 participants
|
54 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Outcome measures
| Measure |
Incident All-cancer Patients
n=19564 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=188924 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
19468 participants
|
188199 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
31 participants
|
254 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
30 participants
|
225 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
35 participants
|
246 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
19390 participants
|
187532 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
66 participants
|
493 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
44 participants
|
423 participants
|
|
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
64 participants
|
476 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=148 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1396 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
1 participants
|
2 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
147 participants
|
1394 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
1 participants
|
6 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
147 participants
|
1390 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR/95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=148 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1396 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
147 participants
|
1394 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
147 participants
|
1390 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
0 participants
|
2 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=148 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1396 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
147 participants
|
1394 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
147 participants
|
1390 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
0 participants
|
2 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=148 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1396 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
147 participants
|
1390 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
147 participants
|
1394 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
0 participants
|
1 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=148 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=1396 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
147 participants
|
1394 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
147 participants
|
1390 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
0 participants
|
2 participants
|
|
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
0 participants
|
3 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=4600 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=43559 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
4567 participants
|
43260 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
15 participants
|
144 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
4585 participants
|
43415 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
33 participants
|
299 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Outcome measures
| Measure |
Incident All-cancer Patients
n=4600 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=43559 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
4585 participants
|
43415 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
6 participants
|
68 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
3 participants
|
35 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
6 participants
|
41 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
4567 participants
|
43260 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
13 participants
|
138 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
10 participants
|
71 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
10 participants
|
90 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Outcome measures
| Measure |
Incident All-cancer Patients
n=4600 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=43559 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
4585 participants
|
43415 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
5 participants
|
51 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
4 participants
|
52 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
6 participants
|
41 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
4567 participants
|
43260 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
12 participants
|
112 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
11 participants
|
100 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
10 participants
|
87 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=4600 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=43559 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
2 participants
|
24 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
4585 participants
|
43415 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
2 participants
|
21 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
0 participants
|
7 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
0 participants
|
3 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
4567 participants
|
43260 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
6 participants
|
52 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
1 participants
|
10 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Outcome measures
| Measure |
Incident All-cancer Patients
n=4600 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=43559 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
4585 participants
|
43415 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
6 participants
|
52 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
4 participants
|
51 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
5 participants
|
41 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
4567 participants
|
43260 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
14 participants
|
112 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
10 participants
|
103 participants
|
|
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
9 participants
|
84 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his cohort entry was the same as case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident other nervous system cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. Inestimable OR and 95% CI when no gabapentin-exposed cancer cases or no gabapentin-exposed controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=38 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=380 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
38 participants
|
380 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
2 participants
|
1 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
36 participants
|
379 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his cohort entry was same as for case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=38 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=380 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
38 participants
|
380 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
36 participants
|
379 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
1 participants
|
0 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 yr lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=38 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=380 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
38 participants
|
380 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
36 participants
|
379 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
1 participants
|
0 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident other nervous system cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=38 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=380 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
38 participants
|
380 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
36 participants
|
379 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
1 participants
|
0 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
0 participants
|
0 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Outcome measures
| Measure |
Incident All-cancer Patients
n=38 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=380 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
38 participants
|
380 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
36 participants
|
379 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
0 participants
|
0 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
1 participants
|
1 participants
|
|
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
1 participants
|
0 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=2155 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=20382 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
20 participants
|
86 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
2135 participants
|
20296 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
35 participants
|
160 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
2120 participants
|
20222 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Outcome measures
| Measure |
Incident All-cancer Patients
n=2155 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=20382 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
2135 participants
|
20296 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
12 participants
|
34 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
2 participants
|
22 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
6 participants
|
30 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
2120 participants
|
20222 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
17 participants
|
62 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
4 participants
|
30 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
14 participants
|
68 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Outcome measures
| Measure |
Incident All-cancer Patients
n=2155 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=20382 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
2135 participants
|
20296 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
11 participants
|
28 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
2 participants
|
27 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
7 participants
|
31 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
2120 participants
|
20222 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
15 participants
|
53 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
5 participants
|
43 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
15 participants
|
64 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the casePopulation: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=2155 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=20382 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
2135 participants
|
20296 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
5 participants
|
18 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
2 participants
|
6 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
1 participants
|
2 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
2120 participants
|
20222 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
7 participants
|
46 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
2 participants
|
23 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
1 participants
|
6 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Outcome measures
| Measure |
Incident All-cancer Patients
n=2155 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=20382 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
2135 participants
|
20296 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
9 participants
|
33 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
6 participants
|
22 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
5 participants
|
31 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
2120 participants
|
20222 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
15 participants
|
56 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
8 participants
|
45 participants
|
|
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
12 participants
|
59 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1272 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=12167 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (with 2 year lag)
|
9 participants
|
53 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (with 2 year lag)
|
1263 participants
|
12114 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Ever (without 2 year lag)
|
15 participants
|
107 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Never (without 2 year lag)
|
1257 participants
|
12060 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Outcome measures
| Measure |
Incident All-cancer Patients
n=1272 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=12167 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (with 2 year lag)
|
1263 participants
|
12114 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (with 2 year lag)
|
4 participants
|
21 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (with 2 year lag)
|
2 participants
|
15 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (with 2 year lag)
|
3 participants
|
17 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Never (without 2 year lag)
|
1257 participants
|
12060 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 1 (without 2 year lag)
|
6 participants
|
46 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 2 (without 2 year lag)
|
3 participants
|
29 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Tertile 3 (without 2 year lag)
|
6 participants
|
32 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Outcome measures
| Measure |
Incident All-cancer Patients
n=1272 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=12167 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
1263 participants
|
12114 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (with 2 year lag)
|
3 participants
|
16 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (with 2 year lag)
|
3 participants
|
22 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (with 2 year lag)
|
3 participants
|
15 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
1257 participants
|
12060 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 1 (without 2 year lag)
|
5 participants
|
32 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 2 (without 2 year lag)
|
4 participants
|
44 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Tertile 3 (without 2 year lag)
|
6 participants
|
31 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Outcome measures
| Measure |
Incident All-cancer Patients
n=1272 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=12167 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (without 2 year lag)
|
4 participants
|
7 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (with 2 year lag)
|
1263 participants
|
12114 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (with 2 year lag)
|
2 participants
|
6 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 2 year (with 2 year lag)
|
0 participants
|
2 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (with 2 year lag)
|
0 participants
|
1 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Never (without 2 year lag)
|
1257 participants
|
12060 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 1 year (without 2 year lag)
|
4 participants
|
16 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
> 3 year (without 2 year lag)
|
2 participants
|
3 participants
|
PRIMARY outcome
Timeframe: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Outcome measures
| Measure |
Incident All-cancer Patients
n=1272 Participants
Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
|
Matched Controls for Incident All-cancer Patients
n=12167 Participants
Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
|
|---|---|---|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (with 2 year lag)
|
1263 participants
|
12114 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (with 2 year lag)
|
4 participants
|
15 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (with 2 year lag)
|
3 participants
|
19 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (with 2 year lag)
|
2 participants
|
19 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Never (without 2 year lag)
|
1257 participants
|
12060 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 1 (without 2 year lag)
|
5 participants
|
32 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 2 (without 2 year lag)
|
6 participants
|
40 participants
|
|
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Tertile 3 (without 2 year lag)
|
4 participants
|
35 participants
|
Adverse Events
All-Cancer: Cases
All-Cancer: Controls
Stomach Cancer: Cases
Stomach Cancer: Controls
Anal Cancer: Cases
Anal Cancer: Controls
Lung Cancer: Cases
Lung Cancer: Controls
Bone/Joint Cancer: Cases
Bone/Joint Cancer: Controls
Breast Cancer: Cases
Breast Cancer: Controls
Penile Cancer: Cases
Penile Cancer: Controls
Bladder Cancer: Cases
Bladder Cancer: Controls
Other Nervous System Cancer: Cases
Other Nervous System Cancer: Controls
Pancreatic Cancer: Cases
Pancreatic Cancer: Controls
Renal Cancer: Cases
Renal Cancer: Controls
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
GSK Response Center
GlaxoSmithKline
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER